Abpro Holdings Inc., in collaboration with Celltrion, Inc., has submitted an investigational new drug $(IND)$ application to the U.S. Food and Drug Administration (FDA) for ABP-102/CT-P72, a HER2 × CD3 T cell engager designed for improved selectivity in treating HER2-positive cancers. The IND submission supports the initiation of a phase 1 clinical trial, anticipated to begin in the first half of 2026, pending FDA regulatory clearance. This marks the first IND submission by Abpro for a solid tumor indication and represents a key milestone in the joint development efforts between Abpro and Celltrion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601991-en) on December 15, 2025, and is solely responsible for the information contained therein.